Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.

Thitima Kongnakorn,Florian Wagenlehner,Marco Falcone,Eszter Tichy,Roberto Di Virgilio,Nathalie Baillon-Plot,Claudie Charbonneau

International Journal of Antimicrobial Agents（2019）

引用 15|浏览10

暂无评分

摘要

•First cost-effectiveness analysis of ceftazidime/avibactam (CAZ-AVI) vs. imipenem in complicated urinary tract infections (cUTIs)•Net incremental cost of €1015/patient with CAZ-AVI vs. imipenem•Incremental cost-effectiveness ratio of €8039/QALY (€30 000/QALY threshold in Italy)•Better health outcomes at an acceptable cost with CAZ-AVI vs. imipenem

查看译文

关键词

CAZ-AVI (or ceftazidime/avibactam),Cost-effective analysis,Economic evaluation,RECAPTURE,Resistance,UTI (or urinary tract infection)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要